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C
arbonaceous nanoparticles (CNPs)
and their derivatives have been
widely used for a number of applica-
tions, including energy storage devices,
superconducting products, magnets, biolo-
gic materials, and catalysts. Numerous stud-
ies have focused on the toxicity issues
associatedwith CNP exposure, while limited
information is currently available regard-
ing their immunomodulating potential.
Growing evidence indicates that local
inflammatory responses following CNP ex-
posure can result in modified systemic im-
mune reactivity.13
Pulmonary inflammation provides a
broad spectrum of signals facilitating re-
cruitment and/or activation of various im-
mune cells, associated with release of
chemokines, cytokines, growth factors, and
“danger” signals. In allergic asthma, T helper
2 (Th2)-type lymphocytes play a major role
in triggering inflammatory responses. Upon
* Address correspondence to
ats1@cdc.gov.
Received for review December 17, 2013
and accepted May 21, 2014.
Published online
10.1021/nn406454u
ABSTRACT Several lines of evidence indicate that exposure to nanoparticles
(NPs) is able to modify airway immune responses, thus facilitating the develop-
ment of respiratory diseases. Graphene oxide (GO) is a promising carbonaceous
nanomaterial with unique physicochemical properties, envisioned for a multitude
of medical and industrial applications. In this paper, we determined how exposure
to GO modulates the allergic pulmonary response. Using a murine model of
ovalbumin (OVA)-induced asthma, we revealed that GO, given at the sensitization
stage, augmented airway hyperresponsiveness and airway remodeling in the form
of goblet cell hyperplasia and smooth muscle hypertrophy. At the same time, the
levels of the cytokines IL-4, IL-5, and IL-13 were reduced in broncho-alveolar lavage (BAL) fluid in GO-exposed mice. Exposure to GO during sensitization
with OVA decreased eosinophil accumulation and increased recruitment of macrophages in BAL fluid. In line with the cytokine profiles, sensitization with
OVA in the presence of GO stimulated the production of OVA-specific IgG2a and down-regulated the levels of IgE and IgG1. Moreover, exposure to GO
increased the macrophage production of the mammalian chitinases, CHI3L1 and AMCase, whose expression is associated with asthma. Finally, molecular
modeling has suggested that GO may directly interact with chitinase, affecting AMCase activity, which has been directly proven in our studies. Thus, these
data show that GO exposure attenuates Th2 immune response in a model of OVA-induced asthma, but leads to potentiation of airway remodeling and
hyperresponsiveness, with the induction of mammalian chitinases.
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allergen sensitization, they release inflammatory cyto-
kines, IL-4 and IL-13, both of which stimulate B cells to
synthesize IgE, and IL-5 necessary for initiating eosino-
philic inflammation,4 while suppressing the Th1 type of
immune responses.58 Several CNPs, including carbon
nanotubes and carbon black, potentiate the pulmon-
ary allergic responses by stimulating Th2-mediated
immunity.912 While exposure to [Gd@C(82)(OH)(22)](n)
nanoparticles stimulated Th1-type responses,13 pul-
monary exposure to multiwalled (MW) and single-
walled (SW) carbon nanotubes (CNTs) has induced
nonspecific suppression of proliferative responses of
splenic T cells.1,3,14 Furthermore, exposure to nanopar-
ticles during allergen sensitization results in a signifi-
cant decrease in both airway reactivity and Th2-type
cytokines compared to animals treated with allergen
alone, suggesting specific immunomodulatory proper-
ties of CNPs.15 Taken together, these studies suggest
that CNPs with different physical and chemical proper-
ties, such as surface area, charge, structure, and size,
can facilitate allergic inflammation.1618
A polysaccharide chitin, the second most abundant
biopolymer in the world that can be found in the cell
walls of fungi, microfilarial sheaths of helminths, and
exoskeletons of insects and crustaceans, is emerging as
a new important allergen.19 Analysis of dust collected
from the homes of asthmatic individuals revealed the
presence of the chitin as environmentally widespread
and associated with β-glucans, possibly from ubiqui-
tous fungi.20 This attracted significant attention to
chitinases, hydrolytic enzymes that break down glyco-
sidic bonds in chitin. Although mammals do not pro-
duce chitin, they have two functional chitinases
(chitotriosidase CHIT1 and acidic mammalian chitinase
CHIA/AMCase) as well as chitinase-like proteins (such
as BRP-39/YKL-40) that have high sequence similarity
but lack chitinase activity.21 Human chitinases may be
related to allergies, and asthma has been linked to
enhanced chitinase expression levels.22 Chitinase-3-
like protein 1 (CHI3L1), also known as BRP-39 in mice
or YKL-40 in humans, is a glycoprotein secreted by
activated macrophages, chondrocytes, neutrophils,
and synovial cells and is thought to play a role in the
process of inflammation and tissue remodeling.23,24
Chitinases might be involved in pathogenesis of dif-
ferent lung diseases, including asthma, COPD, sarcoid-
osis, pulmonary tuberculosis, pneumonia, and lung
cancer.25 However, it is unknown if chitinases might
be affected by exposure to nanomaterials, especially
during development of asthma.
In this paper, we evaluated how pulmonary expo-
sure to graphene oxide (GO) nanoparticles altered
immune responses, allergic pulmonary inflammation,
airway remodeling, and airway hyperresponsiveness
(AHR) in a murine model of ovalbumin (OVA)-induced
allergic asthma. We assessed the effect of exposure to
GO during both OVA sensitization and OVA challenge.
We compared Th1/Th2 cytokine balance in broncho-
alveolar lavage (BAL) fluid, serologic immunoglobulin
profiles, and patterns of eosinophil, neutrophil, alveo-
lar macrophage, and lymphocyte accumulation in the
lungs in treated animals. We show that pulmonary GO
administration significantly suppresses a classic Th2-
polarized immune response and alters the pattern of
inflammatory cell recruitment in the lungs. Despite
diminished Th2-type response, we observed an in-
creased airway remodeling and AHR in mice receiving
OVA and GO during the sensitization phase. Finally, we
revealed that the mechanism underlying augmented
AHR is attributed to extended airway remodeling, at
least in part, through the induction of mammalian
chitinases by alveolar macrophages upon GO
stimulation.
RESULTS
GO Given at Sensitization, But Not Challenge Phase, Pro-
moted Airway Hyperresponsiveness. To evaluate airway re-
sponsiveness to direct stimulation, we utilized the
methacholine challenge test and a whole body
plethysmography. Administration of GO at the time
of OVA sensitization (GO/SENT) (Figure 1) significantly
increased airway responsiveness to methacholine as
compared to control (PBS) and OVA-only treated mice
(OVA/ALL) up to 2.5-fold (p < 0.05, Figure 2). Impor-
tantly, exposure toGOatOVA challenge (GO/CHAL) did
not cause a statistically significant AHR elevation in
asthmatic mice, suggesting that AHR increase was not
due to acute responses to GO administration.
GO Exposure Facilitated Airway Remodeling in Sensitized
Animals. Microscopic evaluation of the lungs of mice in
PBS control group reveals normal morphology of con-
ducting and respiratory airways (Figure 3A). Lungs of
mice exposed to GO (GO/S/cont group) revealed de-
position of brown-pigmented particles in small airways
and numerous interstitial aggregates of pigment-laden
macrophages (Figure 3B, arrows). GO exposure also
causedmild interstitial lymphocytic infiltration without
evidence of airway remodeling. In OVA-treated asth-
matic animals (Figure 3C), epithelial hypertrophy/
hyperplasia, goblet cell hyperplasia, smooth muscle
hypertrophy, and intense lymphohystiocytic infiltra-
tion were apparent, indicating airway remodeling
(Figure 4). In mice treated with GO during the sensiti-
zation phase (GO/SENT), interstitial aggregates of GO-
laden macrophages were seen (Figure 3D, arrows).
Epithelial hypertrophy/hyperplasia in mice of the GO/
SENT groupwas as noticeable as in theOVA/ALL group,
and other morphologic features of airway remodeling
were more prominent (Figure 4 and Table 1). Com-
pared to theOVA/ALL group, a significant increase in the
number of goblet cells (15 ( 1 vs 10 ( 1 per 100 μm),
subepithelial fibrosis (32( 0.6 μm vs 22( 0.8 μm), and
smooth muscle layer (24( 0.6 μm vs 15( 0.9 μm) was
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Exposure to GO Reduced Eosinophil Accumulation, but Sti-
mulated Macrophage Influx in the Lungs of Asthmatic Mice. A
robust accumulation of eosinophils in BALF, as ex-
pected, accompanied OVA sensitization and challenge
in OVA/ALL mice (up to 1.1 ( 0.2  106 cells/mL vs
none in PBS control). GO exposure at the time of OVA
sensitization (GO/SENT group) reduced eosinophil
counts compared to OVA/ALL-treated mice ((0.5 (
0.1)  106 cells/mL, p < 0.05). GO administration in
nonsensitized animals (GO/S/cont group) did not in-
duce eosinophil influx (Figure 5). However, GO treat-
ment on day 28/29 (GO/C/cont group) and during OVA
challenge (GO/CHAL group) facilitated transient neu-
trophil accumulation in BALF (Figure 5); this effect was
not observed in mice exposed to GO during OVA
sensitization (GO/SENT group) or on day 0 (GO/S/cont).
Neutrophil counts in BAL ofmice exposed toGOduring
OVA challenge (GO/CHAL group) were elevated up to
(0.6 ( 0.3)  106 vs (0.2 ( 0.1)  106 cells/mL in OVA-
only (OVA/ALL group) mice and none in PBS control
animals, respectively (p < 0.05). Interestingly, exposure
to GO during OVA sensitization (GO/SENT group) re-
sulted in the elevation of macrophage counts in the
lungs on day 31 (up to (1.4 ( 0.1)  106 cells/mL in
GO/SENTmice as compared to (0.9( 0.1) 106 cells/mL
in OVA/ALL animals, p < 0.05) (Figure 5). In GO-treated
mice, BALF macrophages contained black particles,
indicating the uptake/internalization of GO by macro-
phages (Figure 5E,F). Lymphocyte accumulation was
apparent in OVA/ALL mice and GO/SENT, but not in
GO/CHAL mice on day 31 after GO exposure (Figure 5).
These results indicate that GO aspiration modified the
inflammatory cell pattern in asthmatic animals, redu-
cing eosinophilic inflammation in favor of the emer-
gence of monocytesmacrophages.
GO Exposure Decreased Th2 Cytokines in BAL Fluid. To
further study the pulmonary responses to GO expo-
sure, the levels of IL-4, IL-5, IL-13, TNF-R, IL-6, IFN-γ, IL-
12p70, IL-10, and IL-17 in BAL fluid of exposed animals
were determined. OVA sensitization/challenge resulted
in substantial elevation of Th2 cytokines in BALF (OVA/
ALL group, Figure 6, p < 0.05). Indeed, in OVA-only
treated mice, IL-4 levels peaked at 260 ( 70 pg/mL.
However, in GO/SENT-treated mice the levels of
IL-4 were significantly decreased and averaged at
80 ( 20 pg/mL (p < 0.05, Figure 6). The levels of
IL-5 in BALF were also reduced in GO/SENT mice as
compared to OVA-only exposed animals (Figure 6,
Figure 1. Schemeof experimental design and details of groups exposed toGO.On day 0 of the experiment, BALB/cmicewere
treated with saline or GO particles via pharyngeal aspiration with or without OVA sensitization by intraperitoneal (ip)
injection. Following this, a booster ip injection of OVA or saline was administered on day 14. On days 28 and 29, mice were
further challengedwith pharyngeal aspiration of eitherOVAor saline or treatedwithGO alongwithOVA.Micewere sacrificed
on day 31, i.e., 48 h after the last OVA challenge. The table summarizes in brief the details corresponding to the different
treatment and exposure groups employed in this study. The treatment groups included (given at day 0; day 14; days 2829)
OVA/ALL (OVA sensitization; OVA boosting; OVA challenge), GO/SENT (OVA sensitization þ GO; OVA boosting; OVA
challenge); and GO/CHAL (OVA sensitization; OVA boosting; OVA challenge þ GO). The control groups included animals
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400 ( 60 pg/mL vs 270 ( 55 pg/mL, respectively,
p < 0.05). IL-13 reached 63 ( 17 pg/mL in OVA-only
exposed mice (OVA/ALL), as compared to 21 (
6 pg/mL in GO/SENT mice or 25 ( 10 pg/mL in GO/
CHAL mice (p < 0.05, Figure 5). Increases in IL-6 and
TNF-R levels were seen only 48 h after GO adminis-
tration in both OVA-sensitized and vehicle-treated
animals (data not shown). The levels of IFN-γ,
IL-12p70, IL-10, and IL-17 in BALF were below the
detection limit of the assay. Overall, GO aspiration
reduced the release of Th2 cytokines in the lungs of
asthmatic mice.
GO Attenuated Th2 Immune Responses in Favor of Th1
Polarization. To evaluate the effects of pulmonary
GO exposure on adaptive immune responses to OVA
sensitization, the levels of total and OVA-specific IgE as
well as OVA-specific IgG1 and IgG2a in the serum were
assessed. OVA sensitization resulted in a dramatic in-
crease in the serum levels of IgE and IgG1 (Figure 7),
as compared to nonsensitized animals. Notably, GO
aspiration substantially decreased both total and
OVA-specific IgE levels (Figure 7, 2000 ( 230 ng/mL
in GO/SENT mice vs 5800 ( 500 ng/mL in OVA/ALL
animals, p < 0.05). OVA-specific IgG1, a Th2-associated
antibody, was also significantly lower in GO/SENTmice
as compared to OVA/ALL counterparts: 40( 3 U/mL vs
60 ( 5 U/mL, respectively (p < 0.05). Importantly, a
Th1-associated immunoglobulin, IgG2a, was signifi-
cantly elevated in GO/SENT mice compared to OVA/
ALL controls: 2400 ( 730 U/mL vs 250 ( 12 U/mL,
respectively (p < 0.05). Administration of GO alone
or vehicle did not result in elevation of any of the
measured immunoglobulins. Taken together, these
results suggest that pulmonary exposure to GO altered
immune responses to OVA, reducing Th2-dependent
and activating Th1-dependent pathways.
GO Exposure Stimulated CHI3L1 and AMcase Accumulation in
the Lungs. To test whether GO exposure altered the
levels of chitinases implicated in asthma development,
the content of CHI3L1 and AMCase in BALF of GO-
treated mice on day 7 postexposure was detected
(Figure 8). In exposed animals, the levels of BALF CHI3L1
was markedly increased and peaked at 147.3 (
26.9 pg/mL, as compared to 7.2( 4.4 pg/mL in control
mice (p < 0.05). BALF AMCase levels were 676.9 (
310.2 ng/mL in exposed mice vs 21.8 ( 10.1 ng/mL in
controls (p < 0.05). These data provide the very first
Figure 2. GO given at sensitization promotes airway hyper-
responsiveness. The responsiveness of mouse airways was
measured on day 31 (i.e., 48 h after the last OVA challenge)
using a single chamber, whole-body plethysmograph sys-
tem. Mice were exposed to increasing concentrations (10,
25, 50 mg/mL) of aerosolized methacholine (MCh). The
baseline was measured for 3 min prior to MCh exposure.
After baseline measurements, MCh is nebulized for 1.5 min,
and airway reactivity was measured (2 min/concentration).
Airway reactivity was expressed as Penh (enhanced pause)
values. For details corresponding to the different treatment
groups please refer to Figure 1. Data are displayed as mean
( SEM for 6 mice per group, *p < 0.05 vs OVA/ALL treat-
ment, and Rp < 0.05 OVA/ALL vs PBS treatment.
Figure 3. GO exposure promotes airway remodeling in allergen-sensitized mice. High and low power views of the light
photomicrographs of representative histopathology ofmouse lung tissue onday 31 postexposure toGOand/orOVA: (A) PBS;
(B) OVA/ALL; (C) GO/S/cont; (D) GO/SENT exposure. The presence of interstitial pigment-laden macrophages containing GO
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evidence that GO could stimulate chitinase accumula-
tion in the lungs of treated mice.
GO Induced CHI3L1 and AMcase in Alveolar Macrophages. To
determine if AM could be the source of CHI3L1 and
AMCase in the lungs of GO-treated mice, the produc-
tion of these chitinases by isolated alveolar macro-
phages (AM) ex vivo was next assessed (Figure 8). The
levels of CHI3L1 in culture supernatants of AM isolated
from GO-treated animals peaked at 99.8( 35.7 pg/mL,
as compared to 7.1 ( 3.6 pg/mL in control cells (p <
0.05). AMCase levels were 632.6 ( 171.4 pg/mL in AM
cultures from exposed mice vs undetectable levels in
controls. These data showed that GO directly stimu-
lated CHI3L1 and AMCase release by AM.
GO Interacts with AMCase and CHI3L1 in Close Proximity to
the Chitin/Oligosaccharide Binding Site. To investigate if GO,
similar to chitins, can directly bind/interact with
chitinases AMCase and CHI3L1, we first performed
molecular modeling studies to predict the interaction
site of GO on chitinases. The preferred binding con-
formations in each case are shown in Figure 9. The GO
was predicted to interact with AMCase and CHI3L1 at
two different binding sites, site1 and site2. Residues
that are predicted to be within 5 Å of GO at each
binding site are listed in Table 2. The preferred binding
site, site1, was located in close proximity to the chitin/
active binding site in AMCase and the oligosaccharide
binding site in CHI3L1, either completely (Figure 9A)
or partially (Figure 9B) blocking the binding cavity.
The predicted binding energies of GO to AMCase
and CHI3L1 at site1 were 20.0 and 19.6 kcal/mol,
respectively. Most importantly, the interaction of GO at
site1, completely occupying the entrance of the active
site cavity, overlaps with the inhibitor binding site in
AMCase (Figure 9A). Especially, the predicted binding
site residues W31, W99, N100, A295, and E297 (Table 2)
Figure 4. Pharyngeal aspiration of GO during OVA-sensitization increases epithelial fibrosis, smooth muscle hypertrophy,
and goblet cell hyperplasia. Photomicrographs of representative mouse lung sections on day 31 postexposure to GO and/or
OVA. Lung sections were stained with PAS/diastase to show goblet cells (in red), with trichome to show epithelial fibrosis (in
blue), and with desmin to show smooth muscles (in brown). The identified morphologic alterations in each case are
highlighted with arrows.
TABLE 1. Morphometric Evaluations of Airway Remodeling upon Pulmonary Exposure to GO in a Murine Model
of Asthmaa
PBS GO/S/cont OVA/ALL GO/SENT
epithelial thickness (in μm) 7.1 ( 0.8 9.1 ( 0.5 24.9 ( 0.9b 27.1 ( 0.9b
smooth muscle thickness (in μm) 6.0 ( 0.4 7.0 ( 0.5 15.0 ( 0.9b 24.1 ( 0.6b,c
subepithelial fibrosis (in μm) 3.0 ( 0.4 3.0 ( 0.5 21.9 ( 0.8b 32.0 ( 0.6b,c
goblet cells (per 100 μm) 2.0 ( 0.6 2.0 ( 0.6 10.0 ( 0.9b 14.6 ( 0.9b,c
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were shown to interact with and stabilize AMCase
inhibitors bisdionin-C and -F and others.26,27 However,
this was not the case for CHI3L1 protein. GO binding to
CHI3L1 at site1 results in the partial occlusion of the
entrance to the cavity. Notably, the chitinase-3-like
proteins such as CHI3L1 lack Chitinase activity due
to mutations within the active site compared to
AMCase.21 Thus, the occlusion of the entrance to the
chitin binding site by GO in AMCase;interfering with
the binding/catalysis/hydrolysis of chitin polymers;
could lead to the inhibition of its activity and/or sig-
naling. Further, these results also suggest that GO
interaction with chitinases, in close proximity to chit-
in/oligosaccharide binding site leading to immobiliza-
tion of chitinases on its surface, could act as a signal of
chitinase insufficiency, triggering their compensatory
synthesis by macrophages.
GO Reduces the Chitinolytic Activity. To verify whether
GO inhibits AMCase enzymatic activity, as predicted by
molecular modeling, we measured chitinolytic activity
in the BAL fluid of mice on day 31 post OVA sensitiza-
tion and/or GO exposure (Figure 10A). The chitinolytic
activity increased significantly in the BAL samples from
mice that were OVA-sensitized and challenged (OVA/
ALL). Treating these mice with GO during OVA sensi-
tization (GO/SENT group) or OVA challenge (GO/CHAL
group) significantly reduced OVA-induced AMCase en-
zymatic activity in the BALF by 56.2% and 8.5%, respec-
tively (Figure 10A). However, GO administration in
nonsensitized (GO/S/cont group) and nonchallenged
Figure 5. GO-induced pulmonary inflammatory responses. Cell profile of bronchoalveolar lavage samples from mice 48 h
after the last OVA challenge (i.e., on day 31 postexposure): (A) eosinophils, (B) neutrophils, (C)macrophages, (D) lymphocytes.
Photomicrographs of BALF cells (cytospin preparations stained with Diff-Quik) from (E) GO/SENT and (F) GO/CHAL groups.
Data are presented as mean( SEM for 6 mice per group, *p < 0.05 vs OVA-ALL treatment (N = 3). Φp < 0.05 OVA/ALL vs PBS
treatment.
Figure 6. Pharyngeal aspiration of GO during OVA-sensitization suppresses Th2 cytokines in the BAL fluid of mice. Cytokine
accumulation in bronchoalveolar lavage samples from mice 48 h after the last OVA challenge (i.e., on day 31 postexposure):
(A) IL-4, (B) IL-13, (C) IL-5. Levels of IFN-γ, IL-10, and IL-12p70 in BAL fluid were below the assay sensitivity. Data are shown as
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(GO/CHAL group) animals did not induce any chitino-
lytic activity (Figure 10A). Further, to provide direct
evidence for the specific inhibition of AMCase activity
by GO, we evaluated the chitinolytic acivity using
recombinant human AMCase (hAMCase), stably ex-
pressed in HEK-293 cells (Figure 10B). After 30 min of
incubation, GO treatment resulted in a concentration-
dependent inhibition of hAMCase activity with an esti-
mated binding constant (KD) of 326.1 ( 29.9 μg/mL.
However, the inhibitory potential of GO was lower
compared to a known inhibitor of AMCase, bisdionin
C (Figure 10C, inset). The KD of bisdionin C was
estimated to 4.3 ( 1.2 μg/mL. Assuming that the
oxygen-containing functionalities;involved in inter-
actions with AMCase;represent only a fraction of the
GO surface, our results strongly suggest that GO binds
and inhibits the activity of AMCase.
DISCUSSION
Airway hyperresponsiveness, pulmonary eosinophi-
lia, and mucus hypersecretion, along with atopic sen-
sitization, are well-described hallmark features of
asthma. Several mouse models have been developed
that closely resemble the human asthmatic pheno-
type. The use of aluminum hydroxide adjuvant in OVA
sensitization protocols followed by OVA challenge has
Figure 7. GO exposure attenuates Th2 immune responses in a murine model of asthma. Levels of total and OVA-specific IgE,
IgG1, and IgG2a in the serum of mice 48 h after the last OVA challenge (i.e., on day 31): (A) total IgE, (B) OVA-specific IgE, (C)
OVA-specific IgG1, (D) OVA-specific IgG2a. Data are displayed as mean ( SEM for 6 mice per group, *p < 0.05 vs OVA/ALL
treatment, and Φp < 0.05 OVA/ALL vs PBS treatment (N = 3).
Figure 8. GO stimulates accumulation of chitinases (AMCase and CHI3L1) in the lungs of mice. Levels of chitinase 3-like 1
(CHI3L1) and acidic mammalian chitinase (AMCase) were evaluated in BAL fluid of mice 7 days after exposure to GO (A, B) or
supernatants from cultured BALmacrophages: (A) AMCase; (B) CHI3L1. Alveolarmacrophageswere isolated fromBAL fluid of
mice exposed to GO or vehicle (24 h after exposure). The adherent cells (macrophages) were collected and seeded at a
concentration of 2  105 cells/mL in 96-well plates in complete medium in the presence of recombinant mouse IL-4 (1000
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been shown to produce a robust Th2-mediated asthma-
like disease in mice.28,29 Numerous recent studies
have stipulated on the detrimental effects of pulmon-
ary nanoparticle exposure on immune-mediated dis-
eases. In particular, carbon nanotubes, carbon black,
and diesel exhaust particles (DEP) have been reported
to potentiate Th2-driven type I hypersensitivity reac-
tions in several murine models of asthma.10,11,30 Gra-
phene oxide is a promising carbonaceous nano-
material with unique physicalchemical properties sug-
gested for various medical and industrial applications.
Recent studies have shown that GO can cause acute
inflammation andhas the potential to induce severe and
persistent lung injury in animal models.3133 However,
the effects of pulmonary exposure to GO on immune
responses and pathological outcomes in murinemodels
of asthma have not been previously investigated.
Here we have demonstrated that pulmonary GO
exposure upon initial OVA sensitization augments air-
way responsiveness as measured by the methacholine
challenge method. As methacholine acts directly on
airway smooth muscle, our data indicate that airway
smooth muscle hypertrophy is more prominent in the
GO/SENT group than in the OVA/ALL group (Figure 2).
Airway remodeling, including subepithelial fibrosis,
airway smooth muscle hypertrophy and/or hyperpla-
sia, increased vascularity, and changes in extracellular
matrix, often develops secondary to airway inflam-
mation.3438 A combination of increased contracti-
lity/mass of the airway smooth muscle, increased air-
way wall thickness, and reduced airway caliber has
been implicated in AHR.39 In our study, histopathologic
evaluation of the airways inmice exposed toGOduring
sensitization revealed that goblet cell hyperplasia and
Figure 9. Molecular modeling of GO binding to AMCase and CHI3L1. The two predicted binding poses of GO, site1 and site2,
in each case are represented as sticks and colored in gray andmagenta, respectively: (A) AMCase; (B) CHI3L1. The structures of
chitinases are represented as cartoons and colored red/blue to emphasize the N/C terminus. To highlight the active binding
site cavity of chitinases, bound ligand/cavity space is represented as spheres. The oxygenandhydrogen atoms corresponding
to the organic molecules;such as GO and small molecules bound to CHI3L1;are colored in red and white, accordingly.
TABLE 2. Possible Interaction Sites of Graphene Oxide (GO) on the Chitinases AMCase and CHI3L1a
binding site (no. of
conformations)
binding energy
(in kcal/mol) 5 Å residues
AMCase Site1 (8/9) 20.0 W31, Y34, P36, G37, I69, E70, W99, N100, F101, G102, R145, S217, I272, S286, G287, A288, G289, P290, A291,
G292, P293, A295, K296, E297, S298, N331, V332
Site2 (1/9) 17.8 P149, Q150, K152, H153, I188, S189, Q192, S193, G194, E196, P198, Q199, Q202, Y240, Y245, Y249, K251, D252,
N253, G254
CHI3L1 Site1 (6/9) 19.6 Q33, Y34, E36, N60, W69, E70, W71, W99, N100, F101, G102, Q104, R105, T266, S279, G280, P281, G282, F283,
P284, G285, R286, K289, E290, A291, N323
Site2 (3/9) 19.1 R144, R145, K182, V183, D186, S187, A211, W212, R213, G214, T215, R224, E227, D228, S230, P231, D232, R233,
F234, A268, G275, A276, P277, I278, S279
a A list of all residues (within 5 Å) that stabilize the two predicted binding sites along with the lowest binding energy and the total number of conformations (out of the top 9




SHURIN ET AL . VOL. 8 ’ NO. 6 ’ 5585–5599 ’ 2014
www.acsnano.org
5593
smooth muscle hypertrophy were more prominent
compared to the OVA/ALL group (Figures 3, 4). These
facts suggest that extended airway remodeling in-
duced by GO exposure contributes to the enhanced
AHR in GO-treated mice sensitized to OVA.
Surprisingly, GO exposure upon initial OVA sensiti-
zation suppressed Th2-driven responses. In particular,
GO treatment reduced the levels of IL-4, IL-5, and IL-13
in BALF, aswell as eosinophil accumulation in the lungs
(Figures 5, 6). The Th2-derived cytokines, IL-4 and IL-13,
have been widely implicated in mediating increased
mucus production and early AHR, whereas IL-5 plays a
pivotal role in inducing eosinophilic inflammation.40
Moreover, the levels of OVA-specific and total IgE and
OVA-specific IgG1 were also decreased in the serum of
GO/SENT mice as compared to OVA/ALL animals
(Figure 7). It is well known that IgE-mediated allergic
responses are the most common inducers of AHR,
associatedwith the binding of IgE antibodies to surface
receptors on mast cells and eosinophils and cross-
linking of receptor-bound IgE with antigens, resulting
in the release of inflammatory mediators.41
However, our results show that elevated AHR in GO-
treated mice is independent from eosinophilic airway
inflammation and Th2-mediated immune response
and, thus, is driven by other mechanisms. In contrast
to eosinophil levels, a significant increase in the accu-
mulation of macrophage population was seen upon
GO exposure in the lungs (Figure 5). Several studies
have shown that activated macrophages can pro-
duce large amounts of chitinase and chitinase-
like molecules.4244 We found that GO exposure sub-
stantially increased the levels of both AMCase and
CHI3L1 in BALF (Figure 8). A significant contribution
of mammalian chitinases and chitinase-like proteins
(CLP) to airway remodeling and hyperresponsiveness
was reported recently.45 Considering this, we hypothe-
sized that direct stimulation of macrophages by GO
could induce AMCase and CHI3L1 production by these
cells, contributing to extended airway remodeling and
AHR. We tested this by evaluating the levels of AMCase
and CHI3L1 produced by macrophages isolated from
BALF of animals exposed to GO. Indeed, GO stimulated
the production of the chitinases AMCase and CHI3L1
by macrophages (Figure 8). Chitinases, belonging to
the 18 glycosyl hydrolase family, are expressed in a
wide range of organisms from prokaryotes to eukar-
yotes, including mammals. Chitinases are hydro-
lytic enzymes that break down glycosidic bonds in
chitin, a major component of the insect exoskeletons
and fungal cell walls. In murine allergic models, chitin
administration has been reported to alleviate allergic
responses. Administration of chitin increased alveolar
macrophages, decreased lung eosinophils, and re-
duced IgE levels in the serum. The responses triggered
by GO during OVA sensitization in this study were
strikingly similar to those induced by chitin. Impor-
tantly, chitin molecules modulate innate immune
responses by binding to receptors on cells that speci-
fically recognize pathogen-associated molecular pat-
terns (PAMPs).46,47 Macrophages were shown to be
stimulated by chitin molecules both in vitro and in vivo
via Toll-like receptor (TLR)-dependent mechanisms.48,49
Recent studies have suggested the role of TLRs for
GO-induced effects on macrophages and their uptake
by cells.50,51 On the basis of the similarities in responses
to chitin and GO exposure, we speculate that macro-
phages recognize GO as a PAMP, which, similar to
Figure 10. GO exposure inhibits the chitinolytic activity of
AMCase. (A) Time course of chitinolytic activity in the BAL
fluid of mice 24 h after the last OVA challenge (i.e., on day
31). (B) Dose-dependent changes in the enzymatic activity
of recombinant human AMCase (hAMCase) upon addition
of GO. (C) Decrease in the reaction rate of the enzyme upon
addition of various concentrations of GO. A dose-depen-
dent decrease in hAMCase upon addition of a known
inhibitor, bisdionin C (IC50: 20 μM), is shown as an inset
for comparison purposes. Data are shown as mean ( SEM,
*p < 0.05 vs PBS treatment, and p < 0.05 vs OVA/ALL
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chitin, may be engulfed and phagocytozed. The pre-
sence of particle-laden macrophages in the lung and
BALF (Figures 3, 5E,F) and the predicted interaction
sites of GO in close proximity to the chitin/oligosac-
charide binding site on chitinases further support this
notion (Figure 9).
AMCase has been reported to play a critical role in
airway inflammatory responses and remodeling in
chitin-free conditions, with its expression majorly dri-
ven by Th2 cytokines IL-4 and IL-13.52 Despite sub-
stantial increase in AMCase levels upon GO exposure
(Figure 8), a decrease in eosinophilia in BAL fluid, Th2
inflammation, and serum total IgE was found in mice
treated with GO during sensitization (Figures 57).
Inhibition of the enzymatic/chitinase activity of
AMCase has been previously reported to significantly
alleviate features of allergic inflammation, including
eosinophilia.27,52,53 It was shown that chitinase inhibi-
tors significantly ameliorated Th2 inflammation and
airway hypersensitivity, in part by inhibiting IL-13 path-
way activation, whereas IL-13 caused induction of
AMCase by epithelial cells and macrophages under-
lying the airway hyperresponsivenes and inflammatory
cell infiltration after exposure to an allergen in murine
models of asthma.27,52,53 While our data demonstrated
the GO-induced increase of the expression of AMCase
in the lung, the enzymatic chitinolytic activity was
reduced (Figure 10). The potential for the enzyme
inhibition by GO was further supported by previous
studies, where GO was found to inhibit the activity of
alpha-chymotrypsin.54 This is further corroborated by
our molecular modeling studies, where GO was pre-
dicted to preferentially bind at the entrance of the
catalytic site of AMCase, mimicking interactions with
AMCase inhibitors.26,27 Such interaction of GO with
AMCase, significantly occupying/occluding the open-
ing of the active site (Figure 9A), may interfere with the
role of AMCase in allergic inflammation and asthma. It
is possible that GO affects both the enzyme activity
dependent and independent mechanisms of AMCase.
Under this assumption, GO can down-regulate allergen-
induced IgE production and lung inflammation, includ-
ing eosinophilia in OVA-sensitized mice by interfering
with the enzymatic activity and/or signaling mechan-
isms of AMCase (Figure 11). Future studies involving the
use of transgenic mice deficient in AMCase or CHI3L1
are warranted to establish a direct link between GO
exposure, chitinase stimulation/inhibition, and augmen-
ted airway modeling.
YKL-40, the human homologue of CHI3L1, has been
associated with airway remodeling, hyperresponsive-
ness, and decreased lung function.55 It can directly
increase bronchial smooth muscle cell proliferation
and migration through PAR-2-, AKT-, ERK-, and p38-
dependent mechanisms.56 In our study, the expression
of CHI3L1 in the lung was significantly increased by GO
exposure. At the same time, the degree of airway
remodeling and increased airway hyperresponsive-
ness were more prominent in the GO/SENT group as
compared to OVA/ALL mice and thus may point
Figure 11. Scheme highlighting potential mechanisms of GO-induced airway remodeling and AHR in a murine model of
asthma. Depending on the type of inflammatory cytokines available, macrophages can be activated via a classical (Th1: TNF-
R, IFNγ) or alternative (Th2: IL-4, IL-13) mechanism. Classically activatedmacrophages (M1) exhibit a Th1-like phenotype and
elicit chronic inflammation and tissue injury responses. Alternatively activatedmacrophages (M2), on the other hand, display
a Th2-like phenotype and tend to resolve inflammation and promote wound healing by facilitating anti-inflammatory,
antiapoptotic, and fibrogenic responses. Alternatively activated macrophages may play a major role in several pathologies,
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toward a CHI3L1-dependent mechanism. Interestingly,
Homer et al. reported in two different models of Th2
inflammation that Ym1 and AMCase are exclusively
expressed in proximal and distal airway epithelium,
respectively.57 Differential effects of GO on tested
chitinases in vitro (Figures 9, 10) and differential pene-
tration of GO in the lung tissue may explain the
unexpected bidirectorial effects of GO on Th2 re-
sponses, macrophage and eosinophil homing, and
tissue remodeling in our model of GO modulation of
asthma development. These results may have an im-
portant clinical implication, since it was recently shown
that pediatric patients with severe, therapy-resistant
asthma have higher levels of YKL-40 than do healthy
controls and that YKL-40 might serve as a biomarker of
asthma severity and airway remodeling in children.58
Interestingly, OVA-specific IgG2a, a Th1-associated
antibody, was also substantially elevated exclusively in
GO/SENT mice, providing additional evidence of GO-
induced suppression of Th2-mediated immune re-
sponse in favor of Th1 polarization (Figure 11). How-
ever, this was the case neither in GO-vehicle nor in GO/
CHAL mice (Figure 5). This clearly indicates that the
presence of GO or factors such as chitinases that are
released upon GO stimulation during an allergen
sensitization triggers such responses. This notion is
further supported by previous immunization studies in
mice.59,60 Immunizations using chitinases in the pre-
sence of adjuvants such as aluminum, as used in this
study, elicited strong IgG responses including
IgG2a.59,60 The use of chitosan-based adjuvants during
vaccination also induced significantly enhanced levels
of IgG1 and IgG2a in the serum.46 Further, mice
immunized with Derf2-47-67-loaded chitosan particles
had increased levels of Der f-specific IgG2a in the
serum.61 Thus, it is tempting to speculate that the
induction of chitinases by macrophages upon GO
exposure together with aluminum adjuvant or GO
acting as an adjuvant by itself during allergen sensiti-
zation leads to the induction of IgG2a expression.
However, GO-induced suppression of Th2 responses
in favor of Th1 responses allowing isotype switching in
activated B cells cannot be discounted (see Figure 11
for a schematic summary).
Collectively, our results indicated that GO-induced
immune responses down-regulated Th2-facilitated
IgE production and lung eosinophilia in a mouse
model of asthma, proposing a novel mechanism of
nanoparticle-induced airway remodeling and AHR in
asthma (Figure 11). To this point, we demonstrated
that GO was able to modulate allergic immune re-
sponse in a murine model of OVA-induced asthma. We
showed that GO augmented AHR independently from
eosinophil accumulation and IgE production. We pro-
posed that direct stimulation of mammalian chitinases
in macrophages by GO could be a newmechanism un-
derlying GO-induced airway remodeling (Figure 11).
Further investigations, perhaps with a deeper focus on
understanding the relation between augmented air-
way remodeling and stimulation/activity/signaling
mechanisms of chitinases, are required to fully explore
the mechanisms of immune response modulation in-
duced by GO exposure. Our findings emphasize the
importanceof carefully assessing the immunomodulatory
effects of nanoparticles considered for industrial and
biomedical applications; conversely, if appropriately
controlled, such properties may also be exploited for
therapeutic gain similar to chitosan-based adjuvants in
vaccines.
CONCLUSIONS
Pulmonary exposure to graphene oxide suppressed
Th2-mediated immune response and allergic inflam-
mation in a murine model of asthma. GO aspiration
augmented airway hyperresponsiveness indepen-
dently from eosinophil accumulation and IgE produc-
tion in asthmatic mice. Extended airway remodeling in
GO-treated animals could underlie augmented AHR
and could be partially attributed to the direct GO-
driven stimulation of production of chitinases by
alveolar macrophages. Further investigations are
required to elucidate the detailed mechanisms of
nanoparticle (GO)-driven modulation of Th2 immune
responses in asthma.
METHODS
Particles. Graphene oxide was synthesized and character-
ized as described elsewhere.62 The zeta potential of GO was
32.4. The average particle thickness was 0.61 nm, while the
length and width varied from 20 nm to ∼5 μm. Stock suspen-
sions (1 mg/mL) were prepared before each experiment in PBS,
and the pH was adjusted to 7.0; suspensions were sonicated for
5 min with a probe sonicator (VibraCell, Sonics and Materials
Inc., Newtown, CT, USA) and sterilized by autoclaving. Stock
suspensions were diluted to achieve required concentrations
and sonicated (three 1 min cycles) before use. Endotoxin
content in GO suspensions was evaluated using Limulus
amebocyte lysate chromogenic end point assay kit (Hycult
Biotech, Inc., Plymouth Meeting, PA, USA) according to the
manufacturer's instructions and found to be below the detec-
tion limit (0.01 EU/mL).
Animals. Specific-pathogen-free adult female BALB/c mice
(78 weeks old) were supplied by Jackson Laboratories (Bar
Harbor, ME, USA). Animals were individually housed in the
National Institute for Occupational Safety and Health (NIOSH)
facilities approved by Association for Assessment and Accred-
itation of Laboratory Animal Care International (AAALAC). Mice
were acclimated for at least 1 week. Sterile Sani-Chip bedding
(Harlan Teklad, Madison,WI, USA) was changedweekly. Animals
were supplied with water and food (Harlan Teklad, 7913, NIH-31
modified mouse/rat diet, irradiated) ad libitum and housed
under controlled light, temperature, and humidity conditions.
All experiments were conducted under a protocol approved




SHURIN ET AL . VOL. 8 ’ NO. 6 ’ 5585–5599 ’ 2014
www.acsnano.org
5596
#10-AS-M-009). Six animals per study group were utilized for all
in vivo assays, and all experiments were repeated at least two
times.
As female mice of any strain are generally less aggressive
toward each other and are less apt to fight than the male mice,
they were preferred for studying GO treatment during OVA
sensitization and/or challenge. While it is known that hormonal
influences in females might interfere with toxicity studies,
it is generally accepted that mice from the same lot may
be used when large toxicology studies are employed for
comparing different treatments/exposures. Thus, any hormonal
effects would also be accounted for in the PBS control and
OVA/ALL group; so any effects observed would be due to
GO exposure.
Sensitization, Challenge, and GO Exposures. On day 0 of an
experiment, mice were sensitized to chicken egg ovalbumin
(Hyglos GmbH, Germany) by intraperitoneal injection of a sterile
suspension containing OVA (20 μg/mouse) and aluminum
hydroxide (Al) adjuvant (1.5 μg/mouse, Sigma, St. Louis, MO,
USA) in 100 μL of PBS (Figure 1). Additionally, a group of mice
were exposed to GO or vehicle by pharyngeal aspiration on day
0: a suspension of GO (80 μg/mouse in divalent ion-free PBS) or
PBS was placed posterior in the throat, and the tongue was held
until the suspension was aspirated into the lungs. Booster
injection of OVA (ip, 20 μg/mouse) or vehicle was administered
on day 14. On days 28 and 29, groups were challenged with
pharyngeal aspiration of OVA (10 μg/mouse/day) in PBS or
treated with GO along with OVA (40 μg/mouse/day, 80 μg
cumulative dose). Experimental groups are listed as follows
(Figure 1): treatment group name (treatment at day 0; day 14;
days 2829): OVA/ALL (OVA sensitization; OVA boosting; OVA
challenge), GO/SENT (OVA sensitization þ GO; OVA boosting;
OVA challenge); GO/CHAL (OVA sensitization; OVA boosting;
OVA challengeþ GO). Control groups included animals treated
with GO only (on day 0 or days 2829, GO/s/cont and GO/C/
cont, respectively) or vehicle (PBS). Two days (48 h) after the last
OVA challenge (day 31), mice were sacrificed or used for airway
hyperresponsiveness evaluation. Additional groups of animals
were used for chitinasemeasurements andwere exposed to GO
only as described above.
Airway Hyperresponsiveness Evaluation. The responsiveness of
mouse airways was measured on day 31 using a noninvasive
whole-body plethysmograph (WBP) system (Buxco Systems
Inc., Troy, NY, USA). Briefly, mice were placed in WBP of
approximately 300 mL in which the animals were unrestrained
and exposed to increasing concentrations (10, 25, 50mg/mL) of
aerosolized methacholine (MCh; Sigma-Aldrich). A bias flow of
HEPA filtered room air of 1 LPM was drawn through each WBP.
After acclimatization, the baseline was measured for 5 min prior
to MCh exposure. After the baseline measurements, MCh is
nebulized for 1.5min, andpressure changeswithin the chamber
due to respiration were monitored and recorded (2 min/
concentration). The pressure signals were postprocessed using
Matlab (Mathworks, Inc.) to calculate airway reactivity and
expressed as enhanced pause (Penh) values. Penh is a reason-
able analogue of airway responsiveness to a nonspecific inhaled
stimulus, such as MCh, which provides an acceptedmeasure for
comparison between the experimental groups.
Lung Histopathology and Morphometric Analysis. Lung tissues
were harvested on day 31 of the study and inflation fixed
in situwith 4% paraformaldehyde at 10 cm H2O for 10 min with
the chest cavity open. Paraffin-embedded tissue was cut at a
thickness of 5 μm, stained with hematoxylin and eosin (H&E),
and examined microscopically. Sample identification was
coded to ensure unbiased evaluation. Additionally, a set of lung
tissue sections with a constant thickness of 5 μm was stained
using PAS/diastase to highlightmucus-secreting goblet cells, by
trichrome blue to highlight peribronchial fibrous tissue, and by
desmin immunostain (Ventana Medical Systems, Inc.) to high-
light the peribronchial smoothmuscle. Unbiasedmorphometric
analysis was performed on these stained lung tissue sections
according to the principles and guidelines of basic methodolo-
gical standards in lung morphometry.63 The thickness of re-
spiratory epithelium, subepithelial smooth muscle layer, and
subepithelial fibrous layer was measured using a calibrated
micrometric analyzer (Spot Insight software 5.1). At least 10
randomly chosen regions on each slide were analyzed for
estimating different morphological features including number
of goblet cells, thickness of smooth muscle, and fibrosis in each
case. A standard area measuring 16 400 μm2 was used for the
enumeration of goblet cells. For standardization, the number of
mucus-secreting goblet cells in respiratory epitheliumwas calcu-
lated as number of cells per 100 μmusing the following formula:
total number of goblet cells/total airway circumference 100.64
These evaluations were carried out by a single board-certified
pathologist (DWG) familiar with the guidelines and standards of
toxicologic pathology criteria and nomenclature for mouse
lungs.63,6567 All morphometric measurements were performed
in an unbiased (i.e., blinded) fashion, where the identities of the
various groupsweremasked andwere not knownby the reading
pathologist.
Bronchoalveolar Lavage and Cell Counting. Twenty-four hours
after the last OVA challenge (day 31), mice were sacrificed by
intraperitoneal injection of sodium pentobarbital and exsan-
guinated. The trachea was cannulated with a blunted 22-gauge
needle, and bronchoalveolar lavage was performed with cold
sterile Ca2þ/Mg2þ-free PBS at a volume of 0.7 mL for the first
lavage (kept separate) and 0.8 mL for subsequent lavages. A
total of 5 mL of bronchoalveolar lavage fluid per mouse was
collected and pooled in sterile centrifuge tubes. Pooled BAL
cells were washed in Ca2þ/Mg2þ-free PBS by alternate centri-
fugation (200g, 10 min, 4 C). Cell-free first-fraction BALF
aliquots were frozen and stored at 80 C until processed.
The degree of pulmonary inflammatory response was esti-
mated by the total cell counts, as well as macrophages, neu-
trophils, eosinophils, and lymphocytes recruited into themouse
lungs and recovered from the BALF. Alveolar macrophages,
neutrophils, eosinophils, and lymphocytes were identified in
cytospin preparations stained with a Hema-3 kit (Fisher Scien-
tific, Pittsburgh, PA, USA) by characteristic cell morphology, and
differential counts of BAL cells were performed. Three hundred
cells per slide were counted.
BAL Cytokine Analysis. Levels of cytokines were assayed in the
acellular BAL fluid. The concentrations of TNF-R, IFN-g, IL-12p70,
IL-10, IL-4, IL-5, IL-13, and IL-17 (sensitivity of assays is 57.3pg/mL)
were determined using the BD cytometric bead array, mouse
Inflammation kit (BD Biosciences, San Diego, CA, USA).
Evaluation of Serum Immunoglobulins. Levels of total IgE, as well
as OVA-specific IgE, IgG2a, and IgG1a, were determined in
mouse serum (day 31) using commercially available ELISA kits
(Alpha Diagnostic Intl. Inc., San Antonio, TX, USA) according to
the manufacturer's instructions. Detection of OVA-specific im-
munoglobulins was used for additional identification of Th1- or
Th2-inducing effects of GO.
Alveolar Macrophage Isolation and Culture. BAL cell pellets were
washed three times with PBS and suspended with RPMI-1640
containing 10% heat-inactivated fetal bovine serum, 2 mM
L-glutamine, 200 U/mL penicillin, and 200 mg/mL streptomycin
(Invitrogen). The cell suspension was cultured overnight in
25 cm2 flasks at 37 C in a 5% CO2 humidified milieu to permit
the adherence of AMs. Then the nonadherent cells were removed
by three washes with 2% RPMI-1640. The purity of adherent
AMs was identified to be greater than 95% by morphology. The
adherent cells were collected and seeded in 96-well plates (1.8
106 cells/plate). Forty-eight hours later, culture supernatants were
collected and frozen at 80 C for chitinase assay.
Chitinase Assays. The levels of chitinase 3-like protein 1 and
acidic mammalian chitinase (AMCase or CHIA) were evaluated
in BAL fluid of mice (7 days after exposure) and macrophage
culture supernatants using commercially available ELISA kits.
Mouse CHI3L1 ELISA assay (R&D Systems) was performed
according to the manufacturer's instructions. In brief, samples,
control, and standards (4000 pg/mL) were added to a micro-
plate precoated with a polyclonal antibody specific for mouse
CHI3L1. Unbound substances were washed away, and an
enzyme-linked polyclonal antibody specific for mouse CHI3L1
was added, followed by a wash to remove unbound antibody
enzyme reagents. The AMCase ELISA kit was purchased from
Cusabio Biotech Co. Ltd. (China, http://www.cusabio.com/).
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instructions. In brief, samples and standards (20 ng/mL) were
added to a microplate precoated with an antibody specific for
mouse CHIA. Unbound substances were removed by washing,
followed by the addition of biotin-conjugated antibody specific
for CHIA and subsequent washing. Horseradish peroxidase was
added, and any unbound avidinenzyme reagents were
washed away. For color development in both assays, substrate
solution was added, and the optical density readings at
450540 nmwere proportional to the amount of initially bound
CHI3L1/CHIA.
Molecular Modeling Studies. The three-dimensional structure
of GO was docked to the crystal structure of AMCase (pdbid:
3FXY:A) and CHI3L1 (pdbid: 1HJV:A) using AutoDock Vina68
available at http://vina.scripps.edu. While the presence of rota-
table bonds on the GO ligand structure imparted flexibility,
structures of chitinases were considered to be rigid for docking.
The grid box was centered at coordinates 23.994, 28.478,
35.646 with 80 Å units in the x, y, and z directions for AMCase
and at 24.202, 39.202, 34.858 with 80 Å units in the x, y, and z
directions for CHI3L1. This grid box covered the entire structure
of each chitinase, making the docking unbiased for different
binding sites. The resulting orientations in each case were
clustered based on the position of binding on the receptor
structure. The best ligand-bound chitinase receptor structure in
each case was chosen based on lowest energy as well as the
total number of conformations in that binding site.
Chitinolytic Activity of AMCase. The activity of AMCase was
measured fluorimetrically on the basis of enzymatic hydrolysis
of the 4-methylumbelliferyl-β-D-N,N0 ,N00-triacetylchitotriose (4-
MU-chitotrioside, a substrate for endochitinase) with produc-
tion of 4-methylumbelliferone (4-MU) using CycLex acidic
mammalian chitinase fluorometric assay kit (MBL International,
Woburn, MA, USA). A 10 μL volume of BAL samples (after 200-
fold dilution) was used for the enzymatic assay. Fluorescence
was measured at an excitation of 340 nm and emission of
460 nm for 120 min with 510 min intervals at 30 C. The
activity of AMCase in different samples was estimated by
dividing the relative fluorescence vs reaction time (min). The
inhibitory effects of a known chitinase inhibitor, bisdionin C
(IC50: 20 μM), and GO were investigated using recombinant
human AMCase. Briefly, 10 μL of purified hAMCase (0.3 ng/μL)
and 10 μL of 0.2 mM 4-MU-chitotrioside were added to 80 μL of
chitinase assay buffer containing various concentrations of GO
(01.2 mg/mL) or bisdionin C (08 μg/mL or 020 μM). The
results of the inhibition assays are reported as percent decrease
in activity (ratio of hAMCase activity in the presence and
absence of inhibitor). All samples were assayed in triplicates.
The binding constants of GO and bisdionon C to AMCase were
estimated by fitting the percent decrease in relative fluores-
cence using nonlinear regression.
Statistical Analysis. Values are presented as mean values (
SEM. The significance of treatment-related differences was
evaluated using either two-tailed Student's t test or a nonpara-
metric KruskalWallis ANOVA on Ranks followed by the
HolmSidak test. p values of less than 0.05 were considered
to be statistically significant.
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